Amneal 制药
AMRX
19.18
-0.07
-0.36%
Amneal 制药
US · AMRX
#1854 按市值排名
上市于 1970
19.18
-0.07
-0.36%
实时 - 追踪5344个代码 - 心跳于271秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了4.3个百分点。
机构持股
- 机构持股比例
- 48.23% -4.30pp
- 机构数量
- 379 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider38.19%
Mutual Fund34.78%
Hedge Fund5.80%
VC/PE Fund3.54%
Public Company1.98%
Government Pension Fund0.94%
Insurance Company0.55%
Private Company0.42%
Other13.71%
主要股东 截至 2026-08-10
Tushar Patel
17.61% · 61.34M 股
BlackRock
7.63% · 26.56M 股
Akram Mahesh
5.90% · 20.56M 股
Dipan Patel
4.85% · 16.90M 股
Chirag Patel
4.53% · 15.79M 股
Chintu Patel
3.81% · 13.26M 股
TPG Capital, L.P.
3.54% · 12.33M 股
Vanguard Portfolio Management, LLC
3.48% · 12.14M 股
Rubric Capital Management LP
2.92% · 10.17M 股
Vanguard Capital Management, LLC
2.55% · 8.88M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 35次买入 · 15次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Tushar Patel | -- | 17.61% |
| Chirag Patel | Co-Founder, Co-CEO, President & Director | 4.53% |
| Chintu Patel | Co-Chief Executive Officer | 3.81% |
| Gautam Patel | Director | 0.55% |
| Paul Meister | Independent Chairperson | 0.24% |
| Anastasios Konidaris | Chief Financial Officer | 0.13% |
| Jeffrey George | Independent Director | 0.10% |
| Ted Nark | Independent Director | 0.09% |
| Shlomo Yanai | Independent Director | 0.09% |
| Nikita Shah | Executive Vice President | 0.07% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-16 | J. Buchi | Independent Director | Other Disposition | -20,445 | -- |
| 2026-09-10 | J. Buchi | Independent Director | Derivative Exercise and Retained | +20,445 | $14.45 |
| 2026-08-31 | Andrew Boyer | Executive VP & Chief Commercial Officer of Generics | Other Disposition | -80,000 | -- |
| 2026-08-20 | Andrew Boyer | Executive VP & Chief Commercial Officer of Generics | Other Disposition | -152,426 | -- |
| 2026-08-12 | John Kiely | Independent Director | Other Disposition | -10,000 | -- |
| 2026-08-12 | John Kiely | Independent Director | Open Market Disposition | -50,000 | $17.64 |
| 2026-08-11 | Nikita Shah | Executive Vice President | Open Market Disposition | -146,403 | $17.51 |
| 2026-08-11 | Jason Daly | Chief Legal Officer | Open Market Disposition | -216,613 | $17.40–17.70 |
| 2026-08-10 | J. Buchi | Independent Director | Open Market Disposition | -168,573 | $17.18 |
| 2026-08-09 | Chirag Patel | Co-Founder, Co-CEO, President & Director | Other Acquisition | +6,381,734 | -- |
| 2026-08-09 | Chintu Patel | Co-Chief Executive Officer | Other Acquisition | +6,381,734 | -- |
| 2026-08-09 | Tushar Patel | -- | Other Acquisition | +12,763,469 | -- |
| 2026-08-09 | Gautam Patel | Director | Other Acquisition | +283,632 | -- |
| 2026-05-10 | Deborah Autor | Independent Director | Open Market Disposition | -34,819 | $12.94 |
| 2026-05-06 | Paul Meister | Independent Chairperson | Derivative Exercise and Retained | +48,747 | -- |
| 2026-05-06 | J. Buchi | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Ted Nark | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Shlomo Yanai | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Jeffrey George | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Gautam Patel | Director | Derivative Exercise and Retained | +34,819 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Amneal 制药 讨论区 0 条评论